Psomagen Board Approves USD 75M Capital Surplus Reduction to Offset Accumulated Deficit, No Impact on Shareholder Equity
Psomagen Inc. announced a board resolution on June 30, 2026 to reduce capital surplus paid-in capital in excess of par by USD 75 million to offset accumulated deficit of USD 61.3 million.
The transaction is a statutory book entry under Delaware General Corporation Law requiring only board approval, with no change to total shares outstanding, stated capital, or total shareholders' equity.
Although the reduction amount exceeds 10% of last year's consolidated equity, it involves no cash outflow or new share issuance, purely a balance sheet reclassification.
By eliminating the deficit, the company improves its financial structure and creates capacity for future dividend payments.
[AI Summary]Psomagen's capital surplus reduction to cover accumulated deficit is an accounting adjustment with zero impact on share count or total equity, neutral for existing shareholders. The move strengthens the balance sheet and may enable future shareholder returns.
KOSDAQ Filing Information
Major Management Matters Related to Investment Decision (Decision on Reduction of Capital Surplus and Deficit Compensation (Board Resolution))